Abstract
Purpose :
It has been reported that 0.05% cyclopentolate is effective on phakic patients with asthenopia with accommodative spasm. We evaluated the effect of topical 0.05% cyclopentolate on pseudophakic patients with asthenopia.
Methods :
In this retrospective, observational clinical study, patients with asthenopia after cataract surgery with no known cause other than accommodative spasm were included. There were 6 patients (3 male, 3 female) with 11 eyes. 4 eyes had monofocal intraocular lenses (IOLs), and 7 eyes had multifocal IOLs. The average age was 68.8±5.4. Accommodative spasms were evaluated with HFC (high frequency component) of micro fluctuations measured by an autorefractometer (Speedy-i, Right group). We used a drop of 0.05% cyclopentolate everyday before sleep for the treatment. We evaluated accommodative spasms and subjective symptoms of asthenopia on the first day of treatment and on evaluation day. Two-tailed Student's t-test was used for statistical analysis.
Results :
Patients started their topical treatment 6.8±3.0 months after their surgeries and the evaluation date was 1.7±1.2 months after the start of the treatment on average. All patients had elevated HFC values (68.6±5.0) on the day that the treatment began and had significantly lower HFC values (58.4±2.4, p<0.01) on the evaluation day. Subjective symptoms of asthenopia relieved in 4 out of 6 patients, and they all had multifocal IOLs.
Conclusions :
Topical treatment of 0.05% cyclopentolate may be effective to asthenopia after cataract surgery, especially for patients with multifocal IOLs.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.